FDA retracts HHS plan to deregulate mobile health apps

Listen
Text
  • Small
  • Medium
  • Large

The FDA and HHS are backtracking on previous plans to end regulatory review of 83 mobile health devices after determining the basis for the proposed plan was flawed.

On Jan. 15, HHS published a notice proposing to exempt the mobile health devices from the regulation requirement. The FDA said there is no evidence that HHS consulted with, involved or even notified the FDA before issuing the notice, an April 16 release said.

The January notice said HHS felt the lack of adverse events in unclassified medical devices determined regulation requirements were "no longer necessary to assure the safety and effectiveness of those devices."

Upon further review, HHS and the FDA determined the notice was published without scientific support, contained errors and ambiguities, and was overall flawed.

HHS did not consult or notify the FDA before publishing the notice. 

The FDA said: "It is particularly important that FDA have at least some level of involvement in this type of an action given the expertise needed in evaluating whether a submission under the [regulatory act] is necessary to assure the safety and effectiveness of a device."

 

Copyright © 2021 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars